Global Lyme Disease Treatment Market

Lyme Disease Treatment Comprehensive Study by Type (Doxycycline, Amoxicillin, Cefuroxime axetil, Ceftriaxone, Others), Application (Humans, Animals), Disease (Early Lyme disease (absence of erythema migrans), Lyme carditis, Lyme arthritis, Neurologic Lyme disease, Borrelial lymphocytosis, Post-treatment Lyme Disease Syndrome), Symptoms (Fever, Headaches, Chills, Joint aches, Swollen lymph nodes) Players and Region - Global Market Outlook to 2030

Lyme Disease Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Lyme Disease Treatment Market Scope
Lyme disease is the most common vector-borne disease in the United States. Lyme disease is caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. It is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash and other. Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledGlaxoSmithKline plc (United Kingdom), Pfizer, Inc. (United States), Novartis AG (Switzerland), Almirall, LLC (United States), Mayne Pharma (United States), Galderma Laboratories, L.P. (United States), Lupin Pharmaceuticals, Inc. (United States) and Chartwell Pharmaceuticals (United States)
CAGR%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Lyme Disease Treatment market throughout the predicted period.

GlaxoSmithKline plc (United Kingdom), Pfizer, Inc. (United States), Novartis AG (Switzerland), Almirall, LLC (United States), Mayne Pharma (United States), Galderma Laboratories, L.P. (United States), Lupin Pharmaceuticals, Inc. (United States) and Chartwell Pharmaceuticals (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Sun Pharmaceutical Industries Ltd (India) and Amneal Pharmaceuticals LLC. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Lyme Disease Treatment market by Type , by Application (Humans and Animals) and Region with country level break-up.

On the basis of geography, the market of Lyme Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

In December 2022, Pfizer announced the beginning of a Phase III clinical trial to confirm the efficacy and safety of a new vaccine that could protect children and adults against Lyme disease. The Lyme vaccine, VLA15, was developed by Valneva in collaboration with Pfizer.


Influencing Trend:
High Investments in Healthcare R&D

Market Growth Drivers:
Rising prevalence of lyme disease and Rising geriatric population

Challenges:
Fierce competitive pressure and High cost of treatment

Restraints:
Lack of awareness about the disease and Technical complexities related to diagnostic test

Opportunities:
High governmental healthcare expenditure and Surging insurance penetration

Key Target Audience
Lyme Disease Treatment Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Doxycycline
  • Amoxicillin
  • Cefuroxime axetil
  • Ceftriaxone
  • Others
By Application
  • Humans
  • Animals
By Disease
  • Early Lyme disease (absence of erythema migrans)
  • Lyme carditis
  • Lyme arthritis
  • Neurologic Lyme disease
  • Borrelial lymphocytosis
  • Post-treatment Lyme Disease Syndrome

By Symptoms
  • Fever
  • Headaches
  • Chills
  • Joint aches
  • Swollen lymph nodes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of lyme disease
      • 3.2.2. Rising geriatric population
    • 3.3. Market Challenges
      • 3.3.1. Fierce competitive pressure
      • 3.3.2. High cost of treatment
    • 3.4. Market Trends
      • 3.4.1. High Investments in Healthcare R&D
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lyme Disease Treatment, by Type, Application, Disease, Symptoms and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lyme Disease Treatment (Value)
      • 5.2.1. Global Lyme Disease Treatment by: Type (Value)
        • 5.2.1.1. Doxycycline
        • 5.2.1.2. Amoxicillin
        • 5.2.1.3. Cefuroxime axetil
        • 5.2.1.4. Ceftriaxone
        • 5.2.1.5. Others
      • 5.2.2. Global Lyme Disease Treatment by: Application (Value)
        • 5.2.2.1. Humans
        • 5.2.2.2. Animals
      • 5.2.3. Global Lyme Disease Treatment by: Disease (Value)
        • 5.2.3.1. Early Lyme disease (absence of erythema migrans)
        • 5.2.3.2. Lyme carditis
        • 5.2.3.3. Lyme arthritis
        • 5.2.3.4. Neurologic Lyme disease
        • 5.2.3.5. Borrelial lymphocytosis
        • 5.2.3.6. Post-treatment Lyme Disease Syndrome
      • 5.2.4. Global Lyme Disease Treatment by: Symptoms (Value)
        • 5.2.4.1. Fever
        • 5.2.4.2. Headaches
        • 5.2.4.3. Chills
        • 5.2.4.4. Joint aches
        • 5.2.4.5. Swollen lymph nodes
      • 5.2.5. Global Lyme Disease Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Lyme Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Almirall, LLC (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mayne Pharma (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Galderma Laboratories, L.P. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lupin Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Chartwell Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Lyme Disease Treatment Sale, by Type, Application, Disease, Symptoms and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lyme Disease Treatment (Value)
      • 7.2.1. Global Lyme Disease Treatment by: Type (Value)
        • 7.2.1.1. Doxycycline
        • 7.2.1.2. Amoxicillin
        • 7.2.1.3. Cefuroxime axetil
        • 7.2.1.4. Ceftriaxone
        • 7.2.1.5. Others
      • 7.2.2. Global Lyme Disease Treatment by: Application (Value)
        • 7.2.2.1. Humans
        • 7.2.2.2. Animals
      • 7.2.3. Global Lyme Disease Treatment by: Disease (Value)
        • 7.2.3.1. Early Lyme disease (absence of erythema migrans)
        • 7.2.3.2. Lyme carditis
        • 7.2.3.3. Lyme arthritis
        • 7.2.3.4. Neurologic Lyme disease
        • 7.2.3.5. Borrelial lymphocytosis
        • 7.2.3.6. Post-treatment Lyme Disease Syndrome
      • 7.2.4. Global Lyme Disease Treatment by: Symptoms (Value)
        • 7.2.4.1. Fever
        • 7.2.4.2. Headaches
        • 7.2.4.3. Chills
        • 7.2.4.4. Joint aches
        • 7.2.4.5. Swollen lymph nodes
      • 7.2.5. Global Lyme Disease Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lyme Disease Treatment: by Type(USD Million)
  • Table 2. Lyme Disease Treatment Doxycycline , by Region USD Million (2018-2023)
  • Table 3. Lyme Disease Treatment Amoxicillin , by Region USD Million (2018-2023)
  • Table 4. Lyme Disease Treatment Cefuroxime axetil , by Region USD Million (2018-2023)
  • Table 5. Lyme Disease Treatment Ceftriaxone , by Region USD Million (2018-2023)
  • Table 6. Lyme Disease Treatment Others , by Region USD Million (2018-2023)
  • Table 7. Lyme Disease Treatment: by Application(USD Million)
  • Table 8. Lyme Disease Treatment Humans , by Region USD Million (2018-2023)
  • Table 9. Lyme Disease Treatment Animals , by Region USD Million (2018-2023)
  • Table 10. Lyme Disease Treatment: by Disease(USD Million)
  • Table 11. Lyme Disease Treatment Early Lyme disease (absence of erythema migrans) , by Region USD Million (2018-2023)
  • Table 12. Lyme Disease Treatment Lyme carditis , by Region USD Million (2018-2023)
  • Table 13. Lyme Disease Treatment Lyme arthritis , by Region USD Million (2018-2023)
  • Table 14. Lyme Disease Treatment Neurologic Lyme disease , by Region USD Million (2018-2023)
  • Table 15. Lyme Disease Treatment Borrelial lymphocytosis , by Region USD Million (2018-2023)
  • Table 16. Lyme Disease Treatment Post-treatment Lyme Disease Syndrome , by Region USD Million (2018-2023)
  • Table 17. Lyme Disease Treatment: by Symptoms(USD Million)
  • Table 18. Lyme Disease Treatment Fever , by Region USD Million (2018-2023)
  • Table 19. Lyme Disease Treatment Headaches , by Region USD Million (2018-2023)
  • Table 20. Lyme Disease Treatment Chills , by Region USD Million (2018-2023)
  • Table 21. Lyme Disease Treatment Joint aches , by Region USD Million (2018-2023)
  • Table 22. Lyme Disease Treatment Swollen lymph nodes , by Region USD Million (2018-2023)
  • Table 23. South America Lyme Disease Treatment, by Country USD Million (2018-2023)
  • Table 24. South America Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 25. South America Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 26. South America Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 27. South America Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 28. Brazil Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 29. Brazil Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 30. Brazil Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 31. Brazil Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 32. Argentina Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 33. Argentina Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 34. Argentina Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 35. Argentina Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 36. Rest of South America Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 37. Rest of South America Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 38. Rest of South America Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 39. Rest of South America Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 40. Asia Pacific Lyme Disease Treatment, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 42. Asia Pacific Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 43. Asia Pacific Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 44. Asia Pacific Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 45. China Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 46. China Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 47. China Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 48. China Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 49. Japan Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 50. Japan Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 51. Japan Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 52. Japan Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 53. India Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 54. India Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 55. India Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 56. India Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 57. South Korea Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 58. South Korea Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 59. South Korea Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 60. South Korea Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 61. Taiwan Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 62. Taiwan Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 63. Taiwan Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 64. Taiwan Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 65. Australia Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 66. Australia Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 67. Australia Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 68. Australia Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 73. Europe Lyme Disease Treatment, by Country USD Million (2018-2023)
  • Table 74. Europe Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 75. Europe Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 76. Europe Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 77. Europe Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 78. Germany Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 79. Germany Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 80. Germany Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 81. Germany Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 82. France Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 83. France Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 84. France Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 85. France Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 86. Italy Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 87. Italy Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 88. Italy Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 89. Italy Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 90. United Kingdom Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 91. United Kingdom Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 92. United Kingdom Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 93. United Kingdom Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 94. Netherlands Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 95. Netherlands Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 96. Netherlands Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 97. Netherlands Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 98. Rest of Europe Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 99. Rest of Europe Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 100. Rest of Europe Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 101. Rest of Europe Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 102. MEA Lyme Disease Treatment, by Country USD Million (2018-2023)
  • Table 103. MEA Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 104. MEA Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 105. MEA Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 106. MEA Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 107. Middle East Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 108. Middle East Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 109. Middle East Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 110. Middle East Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 111. Africa Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 112. Africa Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 113. Africa Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 114. Africa Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 115. North America Lyme Disease Treatment, by Country USD Million (2018-2023)
  • Table 116. North America Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 117. North America Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 118. North America Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 119. North America Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 120. United States Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 121. United States Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 122. United States Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 123. United States Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 124. Canada Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 125. Canada Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 126. Canada Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 127. Canada Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 128. Mexico Lyme Disease Treatment, by Type USD Million (2018-2023)
  • Table 129. Mexico Lyme Disease Treatment, by Application USD Million (2018-2023)
  • Table 130. Mexico Lyme Disease Treatment, by Disease USD Million (2018-2023)
  • Table 131. Mexico Lyme Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Lyme Disease Treatment: by Type(USD Million)
  • Table 141. Lyme Disease Treatment Doxycycline , by Region USD Million (2025-2030)
  • Table 142. Lyme Disease Treatment Amoxicillin , by Region USD Million (2025-2030)
  • Table 143. Lyme Disease Treatment Cefuroxime axetil , by Region USD Million (2025-2030)
  • Table 144. Lyme Disease Treatment Ceftriaxone , by Region USD Million (2025-2030)
  • Table 145. Lyme Disease Treatment Others , by Region USD Million (2025-2030)
  • Table 146. Lyme Disease Treatment: by Application(USD Million)
  • Table 147. Lyme Disease Treatment Humans , by Region USD Million (2025-2030)
  • Table 148. Lyme Disease Treatment Animals , by Region USD Million (2025-2030)
  • Table 149. Lyme Disease Treatment: by Disease(USD Million)
  • Table 150. Lyme Disease Treatment Early Lyme disease (absence of erythema migrans) , by Region USD Million (2025-2030)
  • Table 151. Lyme Disease Treatment Lyme carditis , by Region USD Million (2025-2030)
  • Table 152. Lyme Disease Treatment Lyme arthritis , by Region USD Million (2025-2030)
  • Table 153. Lyme Disease Treatment Neurologic Lyme disease , by Region USD Million (2025-2030)
  • Table 154. Lyme Disease Treatment Borrelial lymphocytosis , by Region USD Million (2025-2030)
  • Table 155. Lyme Disease Treatment Post-treatment Lyme Disease Syndrome , by Region USD Million (2025-2030)
  • Table 156. Lyme Disease Treatment: by Symptoms(USD Million)
  • Table 157. Lyme Disease Treatment Fever , by Region USD Million (2025-2030)
  • Table 158. Lyme Disease Treatment Headaches , by Region USD Million (2025-2030)
  • Table 159. Lyme Disease Treatment Chills , by Region USD Million (2025-2030)
  • Table 160. Lyme Disease Treatment Joint aches , by Region USD Million (2025-2030)
  • Table 161. Lyme Disease Treatment Swollen lymph nodes , by Region USD Million (2025-2030)
  • Table 162. South America Lyme Disease Treatment, by Country USD Million (2025-2030)
  • Table 163. South America Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 164. South America Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 165. South America Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 166. South America Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 167. Brazil Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 168. Brazil Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 169. Brazil Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 170. Brazil Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 171. Argentina Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 172. Argentina Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 173. Argentina Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 174. Argentina Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 175. Rest of South America Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 176. Rest of South America Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 177. Rest of South America Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 178. Rest of South America Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 179. Asia Pacific Lyme Disease Treatment, by Country USD Million (2025-2030)
  • Table 180. Asia Pacific Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 181. Asia Pacific Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 182. Asia Pacific Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 183. Asia Pacific Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 184. China Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 185. China Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 186. China Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 187. China Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 188. Japan Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 189. Japan Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 190. Japan Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 191. Japan Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 192. India Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 193. India Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 194. India Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 195. India Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 196. South Korea Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 197. South Korea Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 198. South Korea Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 199. South Korea Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 200. Taiwan Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 201. Taiwan Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 202. Taiwan Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 203. Taiwan Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 204. Australia Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 205. Australia Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 206. Australia Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 207. Australia Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 209. Rest of Asia-Pacific Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 212. Europe Lyme Disease Treatment, by Country USD Million (2025-2030)
  • Table 213. Europe Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 214. Europe Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 215. Europe Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 216. Europe Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 217. Germany Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 218. Germany Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 219. Germany Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 220. Germany Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 221. France Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 222. France Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 223. France Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 224. France Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 225. Italy Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 226. Italy Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 227. Italy Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 228. Italy Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 229. United Kingdom Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 230. United Kingdom Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 231. United Kingdom Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 232. United Kingdom Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 233. Netherlands Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 234. Netherlands Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 235. Netherlands Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 236. Netherlands Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 237. Rest of Europe Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 238. Rest of Europe Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 239. Rest of Europe Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 240. Rest of Europe Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 241. MEA Lyme Disease Treatment, by Country USD Million (2025-2030)
  • Table 242. MEA Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 243. MEA Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 244. MEA Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 245. MEA Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 246. Middle East Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 247. Middle East Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 248. Middle East Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 249. Middle East Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 250. Africa Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 251. Africa Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 252. Africa Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 253. Africa Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 254. North America Lyme Disease Treatment, by Country USD Million (2025-2030)
  • Table 255. North America Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 256. North America Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 257. North America Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 258. North America Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 259. United States Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 260. United States Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 261. United States Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 262. United States Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 263. Canada Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 264. Canada Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 265. Canada Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 266. Canada Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 267. Mexico Lyme Disease Treatment, by Type USD Million (2025-2030)
  • Table 268. Mexico Lyme Disease Treatment, by Application USD Million (2025-2030)
  • Table 269. Mexico Lyme Disease Treatment, by Disease USD Million (2025-2030)
  • Table 270. Mexico Lyme Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lyme Disease Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Lyme Disease Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Lyme Disease Treatment: by Disease USD Million (2018-2023)
  • Figure 7. Global Lyme Disease Treatment: by Symptoms USD Million (2018-2023)
  • Figure 8. South America Lyme Disease Treatment Share (%), by Country
  • Figure 9. Asia Pacific Lyme Disease Treatment Share (%), by Country
  • Figure 10. Europe Lyme Disease Treatment Share (%), by Country
  • Figure 11. MEA Lyme Disease Treatment Share (%), by Country
  • Figure 12. North America Lyme Disease Treatment Share (%), by Country
  • Figure 13. Global Lyme Disease Treatment share by Players 2023 (%)
  • Figure 14. Global Lyme Disease Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Lyme Disease Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 19. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. Almirall, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 24. Almirall, LLC (United States) Revenue: by Geography 2023
  • Figure 25. Mayne Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 26. Mayne Pharma (United States) Revenue: by Geography 2023
  • Figure 27. Galderma Laboratories, L.P. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Galderma Laboratories, L.P. (United States) Revenue: by Geography 2023
  • Figure 29. Lupin Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Lupin Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Chartwell Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 32. Chartwell Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 33. Global Lyme Disease Treatment: by Type USD Million (2025-2030)
  • Figure 34. Global Lyme Disease Treatment: by Application USD Million (2025-2030)
  • Figure 35. Global Lyme Disease Treatment: by Disease USD Million (2025-2030)
  • Figure 36. Global Lyme Disease Treatment: by Symptoms USD Million (2025-2030)
  • Figure 37. South America Lyme Disease Treatment Share (%), by Country
  • Figure 38. Asia Pacific Lyme Disease Treatment Share (%), by Country
  • Figure 39. Europe Lyme Disease Treatment Share (%), by Country
  • Figure 40. MEA Lyme Disease Treatment Share (%), by Country
  • Figure 41. North America Lyme Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Pfizer, Inc. (United States)
  • Novartis AG (Switzerland)
  • Almirall, LLC (United States)
  • Mayne Pharma (United States)
  • Galderma Laboratories, L.P. (United States)
  • Lupin Pharmaceuticals, Inc. (United States)
  • Chartwell Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Sun Pharmaceutical Industries Ltd (India) , Amneal Pharmaceuticals LLC. (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 183 Pages 60 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lyme Disease Treatment Market Quantitative research analysis
Global Lyme Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Lyme Disease Treatment Market are by type [Doxycycline, Amoxicillin, Cefuroxime axetil, Ceftriaxone and Others], by end use application [Humans and Animals].
The Lyme Disease Treatment Market is gaining popularity and expected to see strong valuation by 2030.
  • Rising prevalence of lyme disease
  • Rising geriatric population

Know More About Global Lyme Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Acne Scar Treatment Comprehensive Study by Type (Laser Treatments, Minor Skin Surgeries, Chemical Peels, Fillers, Others), Application (Minimize Small Scars, Minor Skin Surface Irregularities, Surgic...
$ 3450
Genital Warts Treatment Comprehensive Study by Drug Type (Podophyllotoxin, Imiquimod, Sinecatechins, Podophyllin, 5-FU), Mechanism of Action (Immunomodulators, Immunomodulators; Virus Internalization...
$ 3650
Pancreatic Amylase Reagent Comprehensive Study by Function (Digestion Of Carbohydrate, Producing Glucose), Causes And Risk Factor (Autoimmune diseases, Drinking lots of alcohol, Infections, Gallstone...
$ 3750
Agoraphobia Treatment Comprehensive Study by Application (Hospitals, Specialty Clinic Center, Others), Therapy (Psychotherapy, Cognitive Behavioral Therapy (CBT), Exposure Therapy, Other), Medication...
$ 3650
Trauma Fixation - Comprehensive Study by Type (Internal Fixation, External Fixation), Application (Shoulder Fracture, Wrist Fracture, Femur Fracture, Ankle Fracture, Deformity Fracture, Others), End ...
$ 3650
Ocular Genetic Diagnostics Comprehensive Study by Test Methodologies (Next-generation Sequencing (NGS), Multiplex Ligation-Dependent Probe Amplification (MLPA), Fragment Analysis PCR for Repeat Expan...
$ 3750